MedPath

The Effect of Tinnitus Retraining Therapy on Subjective and Objective Measures of Chronic Tinnitus

Phase 1
Completed
Conditions
Tinnitus
Registration Number
NCT00124800
Lead Sponsor
Tinnitus Research Consortium
Brief Summary

The objective of this study is to examine the efficacy of tinnitus retraining therapy (TRT) as a treatment of chronic tinnitus in people with limited hearing loss. The study design is prospective, randomized, double-blind, with repeated measures. The null hypothesis states there will be no difference in subjective measures of tinnitus severity between subjects treated with standard TRT and subjects treated with sham TRT.

Detailed Description

The specific aims of the study are to:

* Evaluate the efficacy of TRT in reducing the objective magnitude of tinnitus.

* Evaluate the efficacy of TRT in reducing the subjective awareness and impact of tinnitus.

* Determine the therapeutic time course of improvement in tinnitus.

* Determine the long-term improvement in tinnitus derived from TRT.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
41
Inclusion Criteria
  • Chronic non-pulsatile tinnitus
Exclusion Criteria
  • Hyperacusis
  • Subjective hearing loss
  • Objective hearing loss with pure tone average greater than 35 dB sound pressure level (SPL)
  • Evidence of significant depression or suicidal ideation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change in objective measure of tinnitus loudness using psychoacoustic matching task18 months
Change in subjective handicap rating of tinnitus using a standardized questionnaire18 months
Secondary Outcome Measures
NameTimeMethod
Change in subjective ratings of tinnitus loudness, annoyance and awareness18 months

Trial Locations

Locations (1)

Southern Illinois University School of Medicine

🇺🇸

Springfield, Illinois, United States

Southern Illinois University School of Medicine
🇺🇸Springfield, Illinois, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.